Thinthin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thinthin

Property Description
Active ingredient Fictionaline
Form Oral Capsule, Quick-Release
Pharmacological Class Selective H₃ Receptor Modulator
Common Use Supportive cognitive function and alertness
Origin Synthetic (Laboratory-created)
Status Prescription (Rx)

What Kind of Drug is Thinthin and How is it Classified?

Thinthin is a trade name for the active ingredient Fictionaline, a prescription medicine developed and manufactured by Fictional Pharma Inc. It is classified pharmacologically as a Selective H₃ Receptor Modulator. The H₃ receptor targeting is clinically recognized for its differentiated approach in affecting central nervous system signaling.

Thinthin is specifically formulated as a quick-release oral capsule. This unique form is designed for rapid dissolution and absorption, providing a fast onset of effect compared to some standard-release capsule formulations.


What is Thinthin Made of and Where Does it Come From?

Thinthin contains the single active ingredient, Fictionaline, which is a high-purity synthetic compound. This compound is manufactured through controlled chemical processes, ensuring the highest standards of consistency and quality demanded by global regulatory bodies.

The synthetic origin of the active ingredient is a key feature, guaranteeing that the chemical composition is uniform and predictable in contrast to products with botanical sources. This consistency is critical for drugs that interact with the central nervous system, where precision in chemical composition is vital.


What is the Primary Medical Purpose of Thinthin?

The primary medical purpose of Thinthin is its use as a supportive agent for cognitive function, specifically to help manage conditions requiring sustained wakefulness and attentive focus. A typical scenario for its use is to aid individuals who have been medically diagnosed with difficulty maintaining required levels of daytime alertness.

The drug's primary therapeutic goal is to restore a medically necessary baseline of attentive wakefulness. This therapeutic profile aligns with established standards for essential medicines, focusing on clear, defined medical necessity.

What side effects are possible with Thinthin?

Possible Side Effects and Safety Information

The safety profile is based on the official regulatory documentation for the medicine's class (CNS stimulants).

Serious Safety Risks

Official regulatory documents describe a risk of serious cardiovascular events, including sudden death in patients with known serious structural heart abnormalities, and reports of stroke and myocardial infarction (heart attack) in adults. The medicine may also cause new or worsening psychiatric symptoms, such as psychosis (e.g., hallucinations, delusional thinking) or mania, even in patients without a prior history.

Common Adverse Reactions

The most frequently reported side effects include insomnia (trouble sleeping), headache, decreased appetite, weight loss, dry mouth, nausea, anxiety, tachycardia (increased heart rate), and palpitations (pounding heart).

Safety Restrictions and Monitoring

Category Regulatory Statement
Contraindications Use is prohibited with Monoamine Oxidase Inhibitors (MAOIs), in patients with known glaucoma, severe anxiety/agitation, motor tics or a diagnosis of Tourette's syndrome, or known serious structural cardiac disease.
Pediatric Safety Long-term use in children may be associated with growth suppression (reduced weight and height gain), requiring regular monitoring. Children under six may experience higher rates of adverse reactions.
Other Warnings May cause increased blood pressure and heart rate; priapism (prolonged or painful erections) has been reported, often associated with dose changes or discontinuation; and peripheral vasculopathy (e.g., Raynaud's phenomenon) may occur.

All patients must be monitored regularly for changes in blood pressure, heart rate, and psychiatric symptoms. The medicine is classified as a Schedule II controlled substance, indicating a high potential for abuse and dependence.

Overdose and Emergency Response

Overdose and When to Seek Help

This information reflects the documented overdose profile for Thinthin as specified in authoritative governmental regulatory sources.

Documented Overdose Manifestations

Overdose with Thinthin can lead to several severe manifestations, primarily affecting the Central Nervous System (CNS) and Cardiovascular System. Officially documented signs and symptoms may include significant CNS depression, ranging from profound somnolence and confusion to coma. Cardiovascular complications such as marked hypotension (low blood pressure) and tachycardia (rapid heart rate) have been recorded. Overdose is considered potentially life-threatening due to the risk of respiratory compromise and circulatory collapse.

Category Regulatory Statement Basis
Toxicity Risk of respiratory and cardiovascular instability.
Management Supportive measures, continuous observation, and monitoring.
Antidote Status regarding a specific pharmacological antidote is determined by regulatory assessment.

Immediate Emergency Action

Official regulatory documents uniformly mandate that immediate emergency medical attention must be sought upon any known or suspected overdose, regardless of the severity of the symptoms initially observed. Management of an overdose focuses on general supportive care, including maintaining an adequate airway, ensuring ventilation, and monitoring vital signs and cardiovascular function. Prolonged observation in a hospital setting may be required to monitor for the delayed onset or escalation of toxic effects.

Therapeutic Uses of Thinthin

What Thinthin Treats: Main Uses and Benefits

Thinthin is used in conditions that involve symptomatic stress related to the sleep-wake cycle and cognitive function. Addressing excessive daytime sleepiness (EDS) is a goal in managing chronic sleep conditions.

The medication is commonly used across conditions presenting with chronic, disruptive symptoms, including Narcolepsy, Shift Work Disorder, and residual excessive daytime sleepiness in patients with Obstructive Sleep Apnea (OSA) who adhere to primary therapy.

It is relevant in clinical settings where patients require support to overcome the cognitive deficits stemming from their chronic sleep disorder, such as poor sustained attention and impaired vigilance. By promoting a sustained state of alertness, Thinthin helps maintain a sense of stability when symptoms are more noticeable. This supportive action contributes to easing the overall symptom load during periods of heightened discomfort.

“The support provided may help patients cope more steadily with the persistent drowsiness and resulting lack of focus that interferes with essential daily activities.”


Quick Fact: Support for Excessive Daytime Sleepiness Symptoms Thinthin is commonly used to help manage the persistent, overwhelming drowsiness and chronic inability to maintain wakefulness that characterize disorders of excessive somnolence.


Regulatory References

  1. National Institute for Health and Care Excellence (NICE)

Eligibility and Restrictions for Use

Eligibility for Use: Official Regulatory Overview

Official regulatory documentation, such as the FDA and EMA labeling requirements, defines eligibility for using a medicine based on specific clinical and physiological factors. Thinthin is permitted for use by individuals who do not present with any of the formally listed contraindications or specific population restrictions.

Populations That Must NOT Use Thinthin (Contraindications):

The medicine is strictly contraindicated and must not be used by any patient who has a known hypersensitivity or severe allergic reaction to the active substance or any of its inactive components (excipients). Official labeling may also include a prohibition on use in individuals with other specific, coexisting medical conditions that place the patient at an unacceptable risk.

Restrictions and Special Considerations:

Use is not established or recommended for certain populations where safety and efficacy data from clinical trials are limited or absent. These restrictions include:

  • Age: Pediatric use may be prohibited or restricted if adequate studies have not been conducted to confirm safety in patients under a specific age.
  • Physiological State: The official status regarding pregnancy and lactation may advise against use or permit it only after a thorough risk-benefit analysis, based on documented data on potential fetal or infant exposure.
  • Organ Function: Patients with severe hepatic or renal impairment may require special dose consideration or be restricted from use if the medicine's clearance and safety are compromised by the dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns for Thinthin (Fictionaline) as stated in official regulatory information.


Official Regulatory Interaction Constraints

Category Documented Interaction Statement
Contraindicated Combinations Co-administration is formally prohibited with Monoamine Oxidase Inhibitors (MAOIs) and other Selective H₃ Receptor Modulators.
Exposure-Modifying Drugs Co-administration with CYP3A4/5 Inhibitors causes a regulatory-documented increase in Fictionaline exposure; CYP3A4/5 Inducers cause a documented reduction in exposure.
Pharmacodynamic Effects The official label specifies a risk of additive CNS effects when co-administered with Central Nervous System (CNS) Depressants or Alcohol.
Absorption Timing Rule Antacids and other metal cation-containing products require a mandatory separation of at least 2 hours to avoid documented absorption interference.

Population and Consumption Notes

Regulatory documentation notes that interaction severity may be heightened in individuals with severe hepatic impairment. Consumption of a High-Fat Meal is documented to significantly reduce the peak plasma concentration (Cmax) and delay absorption of the quick-release capsule. These restrictions are established to manage the product's pharmacokinetic and pharmacodynamic profile.

Mechanism of Action

Targeting the Brain's Natural Alertness Brake

Fictionaline works by specifically engaging the Histamine H3 Receptors ( H3 Rs) in the Central Nervous System (CNS). These presynaptic receptors usually act as autoreceptors, applying a natural inhibitory brake on the release of the wakefulness-promoting neurotransmitter, histamine. By acting as a selective antagonist or inverse agonist, Fictionaline blocks the receptor, thus removing this molecular brake and directly disinhibiting the histaminergic system. This singular action initiates the cascade that leads to increased signaling within the ascending arousal pathways.


Augmenting Arousal and Excitatory Neurotransmission

The removal of the inhibitory control on histaminergic neurons leads to an immediate and sustained increase in synaptic histamine. Furthermore, the H3 Rs also exist as heteroreceptors on the terminals of other key arousal systems, meaning Fictionaline indirectly augments the release of other arousal-associated neurotransmitters, including acetylcholine and norepinephrine. This combined, multi-pathway modulation increases excitatory signaling across the brain, resulting in a physiological state that favors sustained cortical activation and arousal.


️ Mechanism Constraints and Endogenous Dependence

The molecule’s mechanism operates by adjusting the existing regulatory tone—it cannot create new signaling material. Therefore, the physiological outcome of Fictionaline is fundamentally dependent on the presence and functional capacity of the endogenous histamine system. In situations where the metabolic capacity of the histaminergic neurons is compromised, the mechanism’s ability to modulate neurotransmitter dynamics may be physiologically constrained.

Dosage and Administration Information

The administration of Thinthin (Fictionaline) is subject to specific instructions which detail the route, dose, and proper usage conditions. As an oral medication, Thinthin is provided as a Quick-Release Capsule in strengths of 100 mg and 200 mg.

The established dosing regimen begins with an Initial Dose of 100 mg once daily, typically administered in the morning hours to align with the intent for daytime use. The Maintenance Dose ranges from 100 mg to a Maximum Recommended Dose of 200 mg once daily. Dose adjustments follow a specific titration schedule, which requires several days (e.g., 3 to 7 days) of stable dosing before any increase is permitted.

Administration Constraints and Adjustments

Scope Element Guideline Description
Route of Administration Oral administration only.
Timing in relation to meals May be taken with or without food.
Special Procedural Conditions The capsule must be swallowed whole; it must not be opened, crushed, or chewed.
Missed-Dose Rules Take the next dose at the regularly scheduled time; do not double the dose.

Specific adjustments are required for certain patient populations. For Older Adults (≥65 years) and patients with hepatic impairment, a lower initial dose is required, and any subsequent titration must proceed on a slower schedule. These procedural constraints define the standardized, long-term use protocol for Thinthin.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Thinthin

Evidence for Use in Narcolepsy

The research base is primarily made up of Randomized Controlled Trials (RCTs), which were designed to compare Thinthin (Fictionaline) against an inactive substance (placebo) or sometimes against other medicines. The studies focused on Adults with a narcolepsy diagnosis who met the enrollment criteria for Excessive Daytime Sleepiness (EDS). Outcomes studied included patient-reported assessments of sleepiness (ESS) and objective measurements, such as the Maintenance of Wakefulness Test (MWT), which examined the measured tendency to fall asleep during defined time intervals.

Measurements of both subjective sleepiness reports and objective sustained wakefulness was observed in some studies in the observed populations. Subsequent Meta-analyses have contributed to a broader understanding of symptom patterns. The research structure for this indication has an evidence level designated as High.

Evidence for Use in Residual Sleepiness from Treated Obstructive Sleep Apnea (OSA)

Thinthin was evaluated in Adults who were studied because they still reported Excessive Daytime Sleepiness (EDS) despite maintaining adherence to primary OSA therapy. The research also relied on Randomized Controlled Trials (RCTs). Studies focused on the same objective and subjective measurements as the narcolepsy trials. The evidence quality varies across studies, and the overall research base is considered Moderate due to some variability in subjective response that was observed across different trial findings.

Long-Term Studies and Follow-up

The core efficacy research was generally conducted over short-to-medium-term timeframes, most commonly 8 to 12 weeks. This focus on short-term symptom patterns means that the research provides insight into changes measured during the study period but is more limited in its scope beyond that. Long-term effects and the durability of the observed patterns over many years, long-term effects are not fully established.

What Remains Uncertain About Thinthin Research

The research base includes several documented limitations where certainty remains low.

  • Follow-up durations were limited in the core controlled studies.
  • Data for certain groups, such as older adults or pediatric populations, remain insufficient.
  • Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Pharmacological Studies and Literature Search Platform (Reference for Drug Classification)
  2. Oral Drug Delivery: Absorption and Formulation Factors (MedlinePlus Article)
  3. Chemical Compound Structure and Composition Database (Reference for Synthetic Origin)
  4. National Institute for Health and Care Excellence (NICE) Final Scope Document (Reference for Therapeutic Approaches)

Frequently Asked Questions (FAQ)

Common questions about Thinthin (FAQ)

Q: Is Thinthin generally intended for short-term or long-term use?

A: Studies and official information indicate that the core efficacy research was conducted over short-to-medium-term timeframes, typically 8 to 12 weeks. The long-term effects and the durability of the observed patterns over many years are not fully established by the core controlled studies.

Q: Does Thinthin require any specific monitoring or regular blood tests?

A: Regulatory documents indicate that monitoring is required for changes in blood pressure, heart rate, and psychiatric symptoms. In children, regular monitoring for growth suppression (reduced weight and height gain) is also required.

Q: Are there any known long-term side effects associated with Thinthin use?

A: Official information indicates that long-term effects are not fully established due to limited follow-up duration in the core controlled studies. However, the medicine is associated with risks of serious cardiovascular events (such as stroke or heart attack) and psychiatric symptoms, which require ongoing patient monitoring.

Q: Does Thinthin generally affect energy levels or cause fatigue?

A: The primary medical purpose of Thinthin is to help manage conditions requiring sustained wakefulness and attentive focus. Consistent with this action, insomnia (trouble sleeping) is listed as a very common adverse reaction in the regulatory documents.

Q: Can Thinthin cause changes in mood or anxiety levels?

A: According to the official product information, the medicine may cause new or worsening psychiatric symptoms, such as psychosis (hallucinations or delusional thinking) or mania. Anxiety is also listed as a frequently reported side effect.

Q: Does Thinthin have known interactions with common dietary supplements like vitamins or herbal products?

A: The official label specifies a risk of additive Central Nervous System (CNS) effects when co-administered with certain CNS depressants. For any concern regarding potential interactions with supplements or herbal products, it is important that all products taken are discussed with a healthcare provider.

Q: How does Thinthin generally interact with blood pressure medications?

A: Official information warns that the medicine may cause increased blood pressure and heart rate. This means that patients using blood pressure medication require regular monitoring for changes in these vital signs.

Q: Is Thinthin approved for use in children or adolescents?

A: Use is not established or recommended for certain pediatric populations because safety and efficacy data from clinical trials are limited or absent. Official safety restrictions note that long-term use in children may be associated with growth suppression.

Q: What is the information on using Thinthin for patients over the age of 65?

A: Regulatory guidelines state that for Older Adults (65 years and older), a lower initial dose and a slower dose titration schedule are officially required. The core studies note that data for this specific age group remain insufficient.

Q: Is Thinthin use generally advised during pregnancy?

A: The official regulatory status regarding pregnancy may advise against use or permit it only after a thorough risk-benefit analysis. This decision is based on documented data concerning potential fetal exposure.

Q: What does the official guidance say about using Thinthin while breastfeeding?

A: The official regulatory status regarding lactation may advise against use or permit it only after a thorough risk-benefit analysis. This determination is based on documented data concerning potential infant exposure.

Q: Can people with kidney problems or liver issues use Thinthin?

A: Patients with hepatic impairment (liver issues) require a lower initial dose and slower dose titration. Use may be restricted or require special dose consideration for individuals with severe hepatic or renal impairment (kidney issues), as the medicine's clearance may be compromised.

Q: How is the efficacy of Thinthin measured in clinical studies?

A: Efficacy was measured using patient-reported assessments of sleepiness (e.g., the Epworth Sleepiness Scale, ESS) and objective tests of sustained wakefulness, such as the Maintenance of Wakefulness Test (MWT). The MWT measures the measured tendency to fall asleep during defined time intervals.

Q: What is the typical timeframe before people notice the effects of Thinthin?

A: Thinthin is specifically formulated as a quick-release oral capsule which is designed for rapid dissolution and absorption. This formulation provides a fast onset of effect compared to some standard-release capsule formulations.

Q: Does Thinthin cure the underlying condition, or does it primarily manage symptoms?

A: Official regulatory documents define the medicine's role as a supportive agent for cognitive function. Its purpose is to manage conditions requiring sustained wakefulness and attentive focus, not to cure the underlying disease.

Q: Is Thinthin a brand name, or is a generic version of the medicine available?

A: Thinthin is the trade name for the active ingredient Fictionaline. Official documents address only the approved trade name product and do not specify the current status or availability of a generic version.

Q: Is Thinthin considered an essential tool in treatment, or is it optional?

A: Regulatory guidance indicates that the therapeutic profile of Thinthin aligns with goals outlined in Model Lists for essential medicines. This suggests the medicine addresses a clear, defined medical necessity.

Q: How long does the effect of a single dose of Thinthin usually last?

A: The established dosing regimen for Thinthin is once daily, with the dose typically administered in the morning hours. This supports the intent for sustained effects during the daytime use period.

Q: Is it necessary to gradually stop taking Thinthin, or can it be discontinued immediately?

A: Thinthin is classified as a Schedule II controlled substance, which indicates a high potential for abuse and dependence. Products with this classification often require a gradual reduction in dose under medical supervision to manage discontinuation.

Q: How common are severe allergic reactions to Thinthin?

A: Official product information states that the medicine is strictly contraindicated (prohibited) for any patient who has a known hypersensitivity or severe allergic reaction to the active substance or any of its inactive components.

Q: What are the signs of a serious side effect from Thinthin that require medical attention?

A: The official label describes risks of serious cardiovascular events (including stroke or heart attack), psychosis (hallucinations), and mania. Any sign of these serious risks is generally considered an emergency and requires seeking immediate medical assistance.

Q: What are the general eligibility requirements for being prescribed Thinthin?

A: The medicine is indicated for use in Adults with medically diagnosed conditions such as Narcolepsy or Excessive Daytime Sleepiness (EDS) from Treated OSA. Use is permitted only if the patient does not present with any formally listed contraindications.

Q: Why do some people experience initial gastrointestinal issues when starting Thinthin?

A: Nausea is listed as a frequently reported adverse reaction. The drug affects the Central Nervous System (CNS) by modulating neurotransmitter dynamics, which is a known source of systemic side effects, including gastrointestinal issues.

Q: What stage of clinical trials did Thinthin go through before its approval?

A: The research base includes Randomized Controlled Trials (RCTs) designed to demonstrate safety and efficacy. Drug approvals generally rely on data obtained from controlled trials, typically in Phase 2 and 3, to obtain regulatory clearance for the proposed use.

Q: Where can I find the official Consumer Medicine Information (CMI) leaflet for Thinthin?

A: The official CMI is typically provided as part of the regulatory labeling that accompanies the product. Official instructions require the medicine to be stored in the original container, which includes this required labeling.

Q: What are the risks if Thinthin is accidentally taken by someone who is not prescribed it?

A: Risks include serious cardiovascular events and new or worsening psychiatric symptoms. The drug is strictly contraindicated in individuals with certain conditions, such as structural heart abnormalities. These risks are present even if the individual's specific medical status is unknown.

Q: Is the medication Thinthin known to affect appetite or satiety signals?

A: A frequently reported side effect is decreased appetite and subsequent weight loss. The drug’s mechanism involves modulating neurotransmitter dynamics in the Central Nervous System (CNS), which is linked to the control of appetite and satiety functions.

How should Thinthin be stored and disposed of?

Storage Requirements

Official regulatory documentation requires Thinthin Quick-Release Oral Capsules to be stored at controlled room temperature, typically between 20 C to 25 C. It is mandatory to protect the capsules from moisture and light.

The product must be stored in the original container, which must be kept tightly closed to maintain product integrity. The labeling strictly states do not refrigerate or freeze the medicine. As a safety measure, Thinthin must always be kept out of the sight and reach of children.


Disposal Instructions

To dispose of unused or expired Thinthin, patients must follow local pharmaceutical waste disposal requirements. The official instructions prohibit throwing the capsules into household trash or flushing them down the toilet (wastewater). Unused product should be taken to an approved medicine take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thinthin found in:

A-Z Index: